To include your compound in the COVID-19 Resource Center, submit it here.
Gelesis Inc. (Boston, Mass.) said lead candidate Gelesis100 met one of two co-primary endpoints in the pivotal GLOW weight loss trial. COO David Pass told BioCentury the company
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury